Abstract:Chimeric antigen receptor (CAR) T cells have shown promising results in patients (pts) with B cell malignancies, yet approximately 60% of pts with diffuse large B cell lymphoma (DLBCL) will relapse. Therefore, future efforts are needed to improve the outcomes of these pts. A total of 18 pts with relapsed/refractory B cell malignancies, DLBCL (n=17) and ALL (n=1), were enrolled on a phase 1b/2 study (NCT02772198) of locally produced CD19 CAR T cells. The median age was 40.5 years (range, 23-70). All pts received a lymphodepleting preparative regimen with cyclophosphamide and fludarabine, followed by intravenous infusion of autologous CD19 CAR T cells with a CD28 costimulatory domain. Dosing of CAR T cells was 1-1.5 million CAR+ cells per kg. Clinical response was determined at 28 days following cell administration. Blood samples obtained prior to the lymphodepleting conditioning and at days 7, 14, 21, 30 and 60 after CAR T administration were collected. Cell phenotype was assessed on peripheral blood mononuclear cells (PBMCs) using multiparametric flow cytometry. The manufactured CAR T products (n=9) were also subjected to immunophenotypic analysis. Clinically, 11 of 18 pts (61%) responded to CAR T therapy, 6 (33%) with complete response (CR), and 5 (28%) with partial response (PR). Analysis of manufactured CAR T products (n=9) revealed high CD3+ purity (99%), composed with CD4+ (28%) and CD8+ (72%) T cells. Phenotypic characterization demonstrated marked heterogeneity in the percentages of naïve, central memory, effector memory and effector cells within the CD4+ and CD8+ subsets in the CAR T product. In order to assess the homing potential of CAR T cells, expression of chemokine receptors was evaluated in the product cells. High CXCR3 expression was detected (77% and 96% positive within CD4+ and CD8+ subsets, respectively), indicating high migratory capacity of CAR T cells toward inflamed tissues with high levels of CXCL9 and CXCL10 ligands. Furthermore, co-expression of CXCR4 (56% and 54% positive within CD4+ and CD8+ cells) suggests increased homing ability of the manufactured CAR T toward CXCL12-rich bone marrow microenvironment and lymph nodes. Interestingly, higher CCR7 expression (32% vs 8.5%) and lower CCR6 levels (15% vs 28%) were detected on CD8+ CAR T cells from responding pts who achieved CR and PR (n=6) in comparison to non-responders (n=3), suggesting that less differentiated phenotype together with increased trafficking of CAR T to lymphoid tissue corresponds with improved clinical outcome. Additionally, we assessed the immunoregulatory and senescent/exhausted phenotype in CAR T products. Low percentage of CD4+CD25+CD127- Treg cells (13.5%) was detected, with no correlation to clinical response. However, significantly higher frequency of exhausted CD57+CD39+CD28- cytotoxic CD8+ cells stand out as signature population in CAR T products of non-responders in comparison to CR pts (37% vs 9.5%, p<0.02). It is known that immunosuppressive environment affects CAR T cell activation, dampening anti-tumor responses. Therefore, we next evaluated the frequency and kinetics of regulatory T cells and myeloid suppressor cells in the peripheral blood of the CAR T treated pts. Notably, responding and non-responding pts presented distinct Treg patterns. Pts achieving CR demonstrated modest and delayed increase in Treg cells, reaching maximal frequency of 23% Treg out of CD4+ cells at day 21 post CAR T infusion, declining to basal low levels (12.5%) at day 30. In contrast, non-responders possessed rapidly increasing percentage of Treg cells (35%) at day 14 post-infusion. In line with this finding, notable increase in proportion of immunosuppressive CD11b+CD14+ myeloid cells expressing CD163, CD206 and MERTK M2 markers was detected in blood of non-responders, while pts achieving CR experienced transient increase in myeloid suppressor cells at day 7 that went back to normal levels at day 14. Overall, these results elucidate in part the mechanisms of CAR T traffic, immunosuppressive responses as well as induction of T cell senescence/exhaustion that most probably downregulate CAR T effectiveness as observed in non-responding pts. It is conceivable that deeper understanding of these processes will help not just establishing surrogate markers predicting clinical responses but may lead to new strategies for restoration of CAR T activation, thereby improving their efficacy and patient's prognosis. Disclosures No relevant conflicts of interest to declare.

3115 – SINGLE-CELL RNA SEQUECING REVEALS BRD4 INHIBITOR REDUCING CAR-T CELL EXHAUSTION BY MODULATING BATF AND EGR1

BRD4 inhibitor reduces exhaustion and blocks terminal differentiation in CAR-T cells by modulating BATF and EGR1

Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56

4-1BB-Based CAR T Cells Effectively Reverse Exhaustion and Enhance the Anti-Tumor Immune Response through Autocrine PD-L1 scFv Antibody

Single-cell ATAC-seq Maps the Comprehensive and Dynamic Chromatin Accessibility Landscape of CAR-T Cell Dysfunction.

BATF-mediated regulation of exhausted CD8+ T-cell responses and potential implications for chimeric antigen receptor-T therapy

Abstract 6326: Targeting PRDM1 to enhance CAR T cell efficacy against diffuse large B cell lymphoma (DLBCL)

<i>BATF</i>-mediated regulation of exhausted CD8<SUP>+</SUP> T-cell responses and potential implications for chimeric antigen receptor-T therapy

Sustained Remission of Relapsed or Refractory Mantle Cell Lymphoma after 4-1Bb-based CD19-Directed CAR-T Therapy

Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma

BRD4 PROTAC Degrader ARV-825 Inhibits T-Cell Acute Lymphoblastic Leukemia by Targeting 'undruggable' Myc-pathway Genes

Abstract 6316: Exploring the resistant mechanism of CAR T cell therapy targeting CLDN18.2 by single-cell sequencing

Abstract 2899: Small molecule inhibitor of ubiquitin ligase CBL-B enhanced anti-tumor response of CAR-T and CAR-NK cell therapies

Intrinsic ADRB2 inhibition improves CAR-T cell therapy efficacy against prostate cancer

Upregulation of Senescent/Exhausted Phenotype of CAR T Cells and Induction of Both Treg and Myeloid Suppressive Cells Correlate with Reduced Response to CAR T Cell Therapy in Relapsed/Refractory B Cell Malignancies

Brd4 Inhibition Promotes Trail-Induced Apoptosis By Suppressing The Transcriptional Activity Of Nf-Kappa B In Nsclc

Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity

PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion

BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia

NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors

Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy